Good afternoon, ladies and gentlemen, and welcome to the LENZ Therapeutics' Q2 2024 Conference Call. At this time, all participants are in a listen-only mode. Following prepared remarks from management, we will conduct a question and answer session, and instructions will follow at that time. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Dan Chevallard, Chief Financial Officer. Please go ahead. Thank you. Good afternoon, and thank you to everyone for joining us today to discuss LENZ's Q2 2024 financial results and recent highlights. My name is Dan Chevallard, Chief Financial Officer of LENZ Therapeutics. We are joined today by Eve Schimmelpennink, our President and Chief Executive Officer, and Shawn Olsson, our Chief Commercial Officer. In addition, Dr. Marc Odrich, our Chief Medical Officer, will join us for the question and answer session. Before we begin, I would like to remind you that this call will contain forward-looking statements regarding LENZ's future expectations, plans, prospects, corporate strategy, regulatory and commercial plans and expectations, cash runway projections, and performance. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors and risks, including those discussed in our filings with the Securities and Exchange Commission, and which can also be found on our website. In addition, any forward-looking statements represent only our views as of the date of this webcast and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update such statements. The company encourages you to consult the risk factors contained in our SEC filings for additional detail, including in our Q2 2024 Form 10-Q, which was filed today. With that, I will now turn the call over to Eve. Thank you, Dan, and good afternoon, everyone. The first half of 2024 and recent period has been transformational for LENZ. In short succession, we made our debut on the public markets with a strong investor base and balance sheet, delivered the results of our phase 3 CLARITY trials, which we believe support LNZ100 as the potential best-in-class treatment for presbyopia, concluded a $30 million PIPE financing, and importantly, submitted our NDA to the FDA. I am incredibly proud of the continued excellent execution across the organization and highly confident that we are well on our way to deliver the first and only cyclodextrin-based eye drop for the improvement in near vision in people with presbyopia. Looking ahead, and in line with our previous guidance, we continue to work towards a potential approval by the FDA in mid-2025, and if approved, US launch as early as second half of 2025. Before I review our key achievements in more detail, and as a quick reminder, presbyopia is the inevitable loss of near vision that impacts the daily lives of nearly all people over the age of 45. As the crystalline lens in our eyes hardens with age, the eye is less able to accommodate and focus the incoming light for near vision on the retina, resulting in blurry near vision. Although the progression of presbyopia is gradual, presbyopes often experience an abrupt change in their daily life as the symptoms become more pronounced starting in their mid-40s, when reading glasses or other corrective aids are suddenly necessary to read text or conduct close-up work. To address the daily challenges faced by presbyopes, we are developing a once-daily eye drop that in our CLARITY trials has shown to be capable of improving near vision throughout the full workday without the need for reading glasses. More specifically, in April, we reported positive phase 3 data, which we complemented with capstone data in June, in which LNZ100, our cyclodextrin-based product candidate, continued to show strong performance and best-in-class potential. Highlighting some of the key results of the trial, and for the moment, focusing on the results of CLARITY 2, as this is the direct vehicle control trial, we saw a rapid onset effect, with 71% of participants achieving 3 lines or more of near vision improvement at 30 minutes on the very first day of use of the product. At 3 hours, our primary endpoint, we also observed a 3-line or more responder rate of 71%, and we maintained these high levels for the full workday, with 40% of participants still achieving 3 lines or more of near vision improvement at 10 hours, the last time point measured in our efficacy trials. And these 3-line gains turn out to be only the beginning. 84% of participants achieved at least a 4-line gain during the study and a staggering 52%, at least 5 lines. We also saw a very impressive near universal response to LNZ100, with 95% of participants achieving at least 2 lines of near vision improvement. This is an important measure because it is seen as clinically meaningful. Notably, 69% of the participants still reported this improvement at the end of the day, 10 hours after dosing. Interestingly, we also observed a statistically significant, at least one line of distance vision improvement across the population. In terms of safety, LNZ100 was seen to be well-tolerated, with no treatment-related serious adverse events observed in the over 30,000 treatment days across all three CLARITY trials. Of all reported adverse events, 95% were classified as mild, believed to be transient, and consistent with those observed in previous trials. We also saw that in the rare cases, more specifically 7.6% placebo-corrected, that participant noticed a mostly mild and transient headache following instillation of the drop. This appears to be cephalic and for most, no longer appearing with prolonged use of LNZ100. These strong clinical results and the promise they bring for 128 million presbyopes in the U.S. alone, allowed us to further strengthen our balance sheet with a $30 million investment from Ridgeback Capital in July. We appreciate the significant support and confidence shown by the Ridgeback team and are pleased to add this additional capital as we aim to make LNZ100 the best in class, if not only in class, therapeutic option for the treatment of presbyopia. Lastly, I'm very excited to highlight that we have submitted our NDA for LNZ100 to the FDA, marking a key milestone for the company. Our NDA is a culmination of a development program that, along the way, incorporated valuable feedback and guidance from the FDA. We believe that we have compiled a dossier with strong clinical, manufacturing, and quality data, and we look forward to working with the agency as they review our submission. The first step in this, and following a positive initial review, will be the formal acceptance of our NDA within 60 days of submission. Once the FDA accepts our NDA, the agency must complete their review within 10 months. The date at the end of this period is referred to as the PDUFA date, and once the FDA has provided us with it, we will communicate this with you. As mentioned earlier, and in line with previous guidance, we believe that this PDUFA date can be in the middle of next year, and if our submission leads to approval, could lead to launch of LNZ100 in the U.S. in the second half of 2025. To highlight some of the key areas of focus as we begin to prepare for our potential launch, I will now hand the call over to Shawn Olsson, Chief Commercial Officer. Sean? Thank you, Eve, and thank you all for joining us today. The commercial potential for an effective presbyopia treatment represents one of the largest eye care market opportunities. As Eve stated, presbyopia impacts an estimated 128 million people in the U.S. An incident population that is nearly four times greater than those impacted by dry eye. It is also more than the combined population suffering from dry eye, childhood myopia, macular degeneration, diabetic retinopathy, and glaucoma in the U.S. The first eye drop treatment for presbyopia was approved in 2021 and confirmed that strong consumer desire for an eye drop treatment, as evidenced by initial paid new scripts of 3,000-5,000 per week. Long-term usage beyond the trial period of this product did not materialize, as pilocarpine, even at the high concentration of 1.25%, couldn't deliver the consumer-required performance. We believe this leaves the category wide open for a non-pilocarpine presbyopia eye drop solution that can deliver what consumers desire. Unlocking this market requires an ideal presbyopia eye drop, and we are excited for the prospect of our cyclodextrin-based LNZ100. We believe the commercial potential of LNZ100 was validated in our Phase 3 CLARITY study, with 90% of participants noticing an improvement in near vision and 75 participants indicating they would continue to use LNZ100 after the study, of which 81% plan to use the product four to seven days per week. Together, with our broad inclusion criteria, we believe this positions LNZ100 well for the estimated $3 billion market potential opportunity and in what could potentially be a category of one. In parallel to our recent effort towards our NDA submission, our commercial launch preparedness is well underway. In February 2024, LENZ launched its unbranded EyeAm campaign to educate and excite eye care professionals about future presbyopia solutions. Over 50 key opinion leaders are involved in the campaign, of which many are featured at eyeamselective.com. That is E-Y-E amselective.com, where eye care professionals can learn about the importance of ideal pupil size, iris muscle selectivity, and expected early consumer adopters of presbyopia eye drops. Continuing on that momentum, and to support the projected launch following potential FDA approval, LENZ has fully staffed its commercial leadership team across marketing, sales, and commercial operations with expertise in eye care, direct consumer, influencer, and consumer products goods. From an infrastructure standpoint, LENZ is actively building out its U.S. commercial capabilities, highlighted by completion of our third-party logistics contracting, all in preparation for a potential launch of LNZ100 as early as the second half of 2025. As we think about the commercialization of LNZ100, our strategy is clear and based on three primary pillars. First, we want doctors to recommend us. This requires calling on approximately 15,000 eye care professionals who represent over 85% of the Rx scripts.... with our potential best-in-class product to educate and equip them to recommend LNZ100, and to integrate our solution into their patient offering. Second, we want consumers to request us by name. This requires developing a product brand and consumer campaign that will elicit a strong emotional connection and promotional sensitivity to direct-to-consumer advertising. Third, we want to ensure ease of product access for consumers with a seamless journey to use. This requires enabling consumer to experience the product and move quickly from trial to usage. To support this, our team is building out consumer sampling capabilities and commercial access with multiple channels, including the traditional retail pharmacy as well as home delivery. We look forward to providing further updates and progress on our pre-commercial preparations in the quarters to come as we approach potential approval and launch. With that, I'd now like to hand the call over to Dan Chevallard, our CFO, to step through our financial results. Thank you, Shawn. As has been mentioned, the team has continued to execute across the organization in the Q2 in recent period. On the financial front, we were very pleased to have completed the $30 million private investment in public equity, or PIPE, with Ridgeback in mid-July. I would like to reiterate Eve's comments to say that we are pleased to welcome an investor of Ridgeback's caliber, adding to what is an already strong and supportive investor base in LENZ. Inclusive of the $30 million in proceeds on a pro forma basis, we ended the Q2 with approximately $226.2 million in cash, cash equivalents, and marketable securities, which is anticipated to fund the company's cash runway to post-launch positive operating cash flow. Turning now to our Q2 operating results, our operating expenses and resulting cash burn for the Q2 were substantially in line with our plan. Total operating expenses for Q2 2024 were approximately $14.4 million, compared to $15 million for the same period in 2023. Sequentially, our total operating expenses decreased quarter-over-quarter by 11% from $16.1 million in the Q1 of 2024, as we moved away from costs associated with the recent merger transaction and reduced overall clinical development spend. On our Q1 call, we highlighted that we would anticipate a sharp decline in our research and development expense, expenses in subsequent quarters due to the recent conclusion of our phase 3 CLARITY study, which we certainly have realized in the Q2. Total R&D expenses decreased to $6.9 million in Q2 2024, compared to $12.6 million for the same period in 2023. Sequentially, R&D expenses decreased quarter-over-quarter by 34% from $10.5 million in the Q1 of this year. We anticipate R&D costs to continue to decline over the balance of the year, while shifting our development focus towards pre-approval manufacturing activities. Similarly, and further to our go-forward reallocation of capital towards the commercial organization, total SG&A expenses increased to $7.4 million in Q2 2024, compared to $2.3 million for the same period in 2023, and sequentially increased quarter-over-quarter by 32% from $5.6 million in the Q1 this year. This change was directly attributable to key personnel additions within our commercial leadership team and increases in our pre-commercial planning initiatives. Finally, our net loss per share, both basic and diluted, was $0.40 per share in the Q2 of 2024 on a net loss of $10.3 million, compared to a net loss per share of $7.53 per share in the Q2 of 2023 on a net loss of $14.7 million. As was noted on our Q1 call, we again wanted to remind you that these loss per share figures, calculated on a GAAP basis, consider only weighted average common shares outstanding, which were considerably different in the comparative periods. For example, as a public company with a single class of stock outstanding, Q2 2024 net loss per share was calculated on approximately 25.6 million weighted average common shares outstanding. Compare this to Q2 2023, when, as a then private company with multiple classes of preferred and common stock outstanding, net loss per share was calculated on approximately 2 million weighted average common shares outstanding. Putting the nuances of loss per share aside and the lack of comparability to 2023, we ended Q2 of this year with approximately 25.8 million shares of common stock outstanding. To roll this forward to our July 2024 PIPE, we had approximately 27.4 million shares outstanding following that financing. With that, I'll conclude the financial update for what has been a very productive quarter in recent period, and I'll now turn the call back over to Eve for final remarks. Thanks, Dan. In summary, we are very pleased with the progress that the team has made on all fronts. The recent period has been, and promises to continue to be, a very exciting time at LENZ. With these important achievements and milestones, we now turn our full focus towards preparing for the potential approval and commercialization of LNZ100, and we believe we are well positioned to deliver a once-daily, safe, and rapidly acting treatment to the 128 million individuals living with presbyopia in the United States. With that, I'd like to open up the call for questions. We will now begin the question and answer session. Our first question will come from the line of Pavan Patel with Bank of America. Please go ahead. Hey, guys. This is Pavan Patel on for Jason Gerberry. Congrats on your recent NDA submission, and thanks for taking our questions. The first question is, can you give us an idea of when we should expect SG&A spend to pick up as you begin to incur more meaningful pre-launch investment on your PNL? And then our second question is, maybe if you can remind us how you're thinking about the market opportunity and identifying the patients who would be good candidates for a pharmacotherapy treatment of loss of near vision versus reading glasses. Thank you. Thanks, Pavan. Great questions. I'll hand the first one over to Dan. Sure. Yeah, thanks for the question. Kind of as we said for this quarter, we did see a 32% quarter-on-quarter increase in SG&A, and I think that you should expect us to have a lot of ramp over the balance of this year. I think where you'll really start to see is as we move into 2025, and then subsequently preparing for commercialization, sales force, hiring, et cetera, as we approach the midyear of next year. Thanks. And then as for which patients we would prioritize, Shawn? Yeah. So looking at how we identify the patients that would be good candidates for this drop. So when we think about our product, we had a very broad inclusion criteria. So, you know, we wanted to develop a product that did work for everybody, and that's why we're focused on an all eyes, all-day solution. Now, that being said, there are people that are more prone to be early adopters of an eye drop solution. We commissioned a very large study to do market research in this space, and we really found three groups of individuals that stood out as the earliest adopters, and those three groups fall into people that are in contacts now, entering presbyopia, and want to stay in contacts. They have been looking for... They've been in a glasses-free lifestyle and want to continue that. A big reason for dropout of contacts is because of presbyopia. The second one are people that have had refractive surgery in the past. So again, people who paid for LASIK, invested in glasses-free lifestyle and want to continue it. And thirdly, we found a high correlation to people that have been to a med spa in the past 12 months. Each one of those groups are north of 10 million individuals. Thanks, guys. Great. Thanks, Shawn. Our next question will come from the line of Igor Nakhamovets with Citi. Please go ahead. Hi, Eve and team. Thanks for taking the questions. I had a few. I was just curious, with respect to the target prescriber audience, the optometrists, can you just give some perspective as to what% of the optometrist pool in the United States are currently able to write prescriptions for LNZ100? And then also, what% of the optometrists have the basic ability to perform the retinal eye exam to prescribe LNZ100? Thanks. Absolutely. So this is Shawn Olsson again. So when we think of LNZ100, you know, upon potential approval, those that are able to prescribe it, when we think of the optometrists, nearly all the optometrists across the, all across the U.S. will have the ability to prescribe LNZ100. So it falls into the category of miotics, and with the exception of a couple of states, they will have the ability to prescribe on day one, and so that really covers the vast majority of all optometrists. In terms of doing retinal eye exams, retinal eye exams are going to be a very common process done for, again, nearly every optometrist across the U.S., they will be able to do those retinal eye exams. So in terms of access, we see ourselves in a very good position for access upon approval. Okay, great. And then one other question we've been getting from investors is if you could talk a bit about how you ran your studies and the data that supports the use of LNZ100 in lower light conditions. For example, if you're out at a meal at a restaurant and you need to read the menu, for example. Could you just talk about that aspect of the product profile? Absolutely. So we did all our near vision measurements in what's called mesopic conditions. So mesopic is low light. Just to give you an idea of what that means, so we actually have one of our KOLs describe that, very adequately in our KOL event. That basically means that you lower the lights in the room to almost candlelight conditions. So it's very low light in the room, and then you have them read a backlit screen, screen. So it's truly low light conditions that we've measured all our near vision in. So if you will, it's the most challenging condition because we definitely wanted to avoid that we, you know, brighten the room in a way that it would impact positively near vision that we could not ascribe to our product. So again, very low light, dimly lit conditions in the room. And then just to back up a little bit into Shawn's statement on the retina exam, that's something that all optometrists pretty much do already. So it's a very standard exam, so it's not something that we need to train them on or that we need to, that they need to add to the practice to be able to prescribe a drop. Again, very common practice in optometry. ... Okay, thank you. Thank you. Our next question comes from the line of Joseph Catanzaro with Piper Sandler. Please go ahead. Hey, everybody. Thanks for taking my questions. Maybe, maybe two from me. First, as it relates to the NDA filing, can you just remind us whether there was any formal engagement with the FDA, like a pre-NDA meeting ahead of the filing? And if so, any sort of feedback learnings you sort of gleaned from those interactions? And then second question, I guess, related to early adopters, but less from a patient perspective and more so from a physician perspective, you know, what are you looking for there? Is it simply those who have written a VUITY script in the past, or are there more things that you're honing in on that could potentially identify early, early writers? Thanks. Thanks, Joe. I'll take the first one, and then I'll kick the next one over to Shawn. So yes, there's been definitely an end-of-phase III and pre-submission meeting with the FDA. More importantly, we've had many discussions and engagements with them along the years of our development, and that's where most of the feedback actually came from, the FDA. So we've very well aligned with them on especially our clinical program, manufacturing setup, basically everything that was relevant for the development. And that actually then made the end-of-phase III meeting with them pretty benign. I think there was hardly any questions actually that we had left that we wanted to ask. It was merely a confirmation of, this is all the data that we've gathered, this is the amount of patients that we have on both the efficacy and the safety side. And they once again confirmed that that was completely aligned with their expectations for our NDA. So we're very confident that the filing has, or the submission has everything in it that the FDA wants to see. And for your second question, when we were identifying early adopters from an eye care professional standpoint, again, we commissioned a very large study and took into account many factors. We looked at the prescriptions of VUITY. We looked at early adopters of other recent eye care launches. We also looked at, you know, history of prescriptions for dry eye, as well as different locations, such as urban city centers, where we saw a lot of the VUITY scripts. Ultimately, when we did all the analysis, what came out and was the primary focus of the targeting was their actual propensity to write VUITY and how many scripts they wrote. And that's really where we come up with those 15,000 target ECPs that represent over 85% of all the VUITY scripts. Okay. Our next question will come from the line of Marc Goodman with Leerink. Please go ahead. Yes, hi, could you please review, what you've done on CMC, what's left to do? Just give us an update there, please. Thanks. Absolutely. Thanks, thanks, Mark. Good question. So on the CMC side, or the manufacturing side, we've actually produced all our clinical phase III material at commercial scale. So we're fully set up to produce large quantities at that scale. Our complete supplier network is in very good standing with the FDA, so we're very confident that our commercial network, commercial manufacturing is all in place there. And that goes for both the drug products as well as drug substance or API. Stability all done, everything you need to do there? Yep, stability is all done. So all the stability that we needed to submit our, our program, and this is generic for, for any submissions. You need to submit with at least 12 months of, stability data on your, registration batches, which obviously, given the fact that we've submitted, we have that in place and submitted, and that data all looks, looks stellar. Great. And then just secondly, on the unbranded campaign, can you just go into a little bit of detail, a little more color, just on, you know, what's the discussion, what it's like? Maybe just, you know, give us a sense of what a session would be like and the feedback you're getting. Thank you. Yeah, absolutely. So we're really excited about this unbranded campaign. What's unique to presbyopia is the fact that, you know, when you think about it, everyone knows about reading glasses. We don't have to train them on the disease state. What we have to train people on is how to look for what an ideal presbyopia eye drop solution is. So really what we're talking about is what's the ideal pupil size, you know, the importance of a eye drop that focuses on reducing the pupil, but avoiding that ciliary muscle. And then also because there's so many people out there impacted by presbyopia, you know, who are the early adopters? So a lot of that's training on, you know, those three groups I talked about before: people in contacts, people who've had refractive surgery, and people who have been to a medi spa. Overwhelmingly, what we see at the different conventions is excitement for the campaign. It's very ECP forward, so we have over 50 people that are, you know, the face of the campaign across all of our presentations, all of our conventions, and we actually release a new one every week on LinkedIn. And we're getting calls from doctors saying, "Hey, when is my photo going out? Because I actually wanna—I wanna see my photo on LinkedIn. I wanna like it." So it's going very well. I think what's always really important with our product. You know, the first thing people want to know about the product, and this is separate from the unbranded because we can't commingle the two, but they want to know it's not pilocarpine. That's the really important thing and that doctors care about. As soon as they know it's a non-pilocarpine solution on the medical side, you know, they're very excited to learn more about the product and engage. So we've seen this as a very good success. We've seen a lot of traction and a lot of ECPs coming to us that want to share their excitement for the future of presbyopia solutions. They want us to, they want us to tell them more. Thank you. Our next question comes from the line of Tim Lugo with William Blair. Please go ahead. Hey, guys, this is Lachlan on for Tim. Thanks for taking the questions. As you've shared the data with a wider audience of physicians over the past few months, are there any new findings or sort of nuances that have emerged about how they're thinking of using it, that maybe hadn't really come through fully in your prior market research? And secondly, I believe at the KOL Day, one of the physicians said or suggested that they would, you know, most patients would first try the drop in the office. Is that sort of correct, or is that what you're expecting? Thanks, thanks, Lachlan. Good to, good to hear you. So on, on that first one, and, you know, I'll, I'll keep that very brief because obviously I wanna make sure that, one, we don't talk about anything that's, that's not, on the label yet or that, that we've not studied. But for sure, you know, the, the, the medical community is, is talking and thinking about uses of, of, of how they could see this product being used outside of, of, of near vision. So yeah, that's, that's something that, in that context, is discussed, not something for me to, to elaborate on. In terms of the use of the product, you know, we meet with a lot of different eye care professionals across optometry. You know, many of them want the patient to experience in the office, and what's great about our product is because you have that immediate response that we saw in our trial, people can have that wow effect, you know, right off the bat when they put it in. Now, some doctors, especially those that go for the dilated eye exam, are gonna want them to take the samples home and try it at home. But, we see that, you know, how the ECPs run their practice will decide whether or not they do it in office or outside of the office. It will be a good mix. Got it. Thanks. Just one thing to add there, like, on the data side, just thinking about it some more on what you just asked. One of the things that we've realized that we shared during that KOL event, that what the data shows is that as your presbyopia gets worse, the actual impact keeps up with that. So the worse your presbyopia, the more lines you gain. That's certainly something that we've heard resonate really well in the medical community. So when maybe people initially were thinking about a presbyopia eye drop as something that, you know, could have an effect early on in someone's presbyopia journey, it's very clear now that actually our drop, uniquely, because it is unique to our product, keeps up with how your presbyopia, I guess, gets worse. So if your presbyopia, if you're 20/80 or 20/100, and you would need 4, 5, maybe 6 lines, that's what the product actually delivers for you. So it ties into that very broad age range that we've tested in our trial. Yeah, very interesting. Thanks. Our next question comes from the line of Matthew Caufield with H.C. Wainwright. Please go ahead. Hi, Olsson team. Some very exciting developments for the quarter. So our question was: considering filling a prospective monthly prescription, have you shared how many refills per year could be anticipated among presbyopia patients if or when ultimately approved? Is the baseline assumption that patients could be using the drops daily or more likely on select days per month per patient, kind of based on their scheduling? Any clarity there or thoughts there could be helpful, and excited to see the progress. Thanks. Great. Thank you. This is Shawn again. So a couple comments on that. So in terms of what we found in our market research, people are looking for an everyday eye drop that lasts all day, and we see this across multiple different studies. So not only in our consumer research did we see that the majority of patients wanted to use it 4-7 times a week. When we actually look at the patient-reported outcomes from our phase 3, 81% of the patients that would continue to use the product after the study plan to use it 4-7 days a week. So we do see this much more like contacts, where people want to use it every day. Now, that being said, all medicines, you know, most medicines are not 100% compliant, right? If you look across the board, you know, for contacts, it's about 89% compliance rate for daily contacts. Tyrvaya had about a 65% refill rate. General medicines is about 50%. So when you look at that $3 billion market cap, or $3 billion market size, it assumes a conservative, you know, 5 fills a year or a 42% refill rate. So that's what's built into that $3 billion number. However, when we speak to consumers, they're looking for an everyday eye drop, looking at probably 4-7 days per week. Very helpful. Just to confirm I heard that right, you said five times per year as sort of an average from your analysis? Yeah. So if you think of average medicines are 50% compliance 5 refills a year would just be a little bit conservative to that. That'd be a 42% refill rate. Gotcha. Okay. Understood. Thank you for that. Thanks, Matt. That concludes our question and answer session, as I'm showing no further questions at this time. Thank you for your participation in today's conference. This does conclude the program. You may now disconnect. Please wait. The conference will begin shortly.